Reduction in the hepatocellular carcinoma antioncogene SLC39A14 during the malignant progression of hepatocellular carcinoma

Figure 2 SLC39A14 expression in clinical hepatocellular carcinoma samples. A: Differences in SLC39A14 expression between cancer tissues and paracancerous tissues from hepatocellular carcinoma (HCC) patients were detected by western blotting (n = 13); B: Differences in SLC39A14 mRNA expression in the cancerous and paracancerous tissues of HCC patients were detected by quantitative reverse transcriptase PCR (n = 3). ^aP < 0.01. ^bP < 0.0001.